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Abstract 
Background: Although the incidence of atrial fibrillation (AF) progressively increases 
with age the vast majority of AF ablation is done in middle aged patients. We evaluated 
the feasibility and safety of catheter ablation in patients older than 65 years of age with 
paroxysmal and persistent AF. 
Methods: Out of a total of 230 consecutive AF ablation procedures, 45 patients were 
older than 65 years of age and underwent 53 procedures. The ablation strategy consisted 
of wide-area circumferential lines around both ipsilateral pulmonary veins using a three-
dimensional mapping system.  
Results: The mean age was 69 ±3.5 years (35 males). The mean duration for AF was 8.7 
±6.5 years. 39 had paroxysmal and 6 persistent AF despite use of 1.38 ±0.77 
antiarrhythmic drugs. All patients had a structurally normal heart. 11 had systemic 
hypertension. Mean procedure time was 187 ±33 min. Acute procedural success rate with 
abolition of all pulmonary vein potentials was achieved in all patients. Pericardial 
tamponade requiring percutaneous drainage occurred in one (1.9%) patient. There were 
no cardioembolic events. Among the 43 patients whose clinical outcome was assessed at 
6 months, 34 (79%) had a significant reduction (>90 %) of the total symptomatic AF 
burden, compared to pre-ablation, with a complete lack of symptomatic AF in 32 (74%) 
patients. The success rate was higher for patients with paroxysmal versus persistent AF 
(81 vs. 67%). 6 patients (11 %) underwent repeat procedures. 
Conclusions: Catheter ablation is a safe and effective treatment for patients over the age 
of 65 years with symptomatic, drug-refractory AF. Therefore, patients should not be 
excluded from undergoing AF catheter ablation on the basis of age alone. 
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Background 
Atrial fibrillation (AF) is the most common of all cardiac arrhythmias with an incidence 
and prevalence to be on the rise. AF is a disease of the elderly with a prevalence 
increasing with age.   Up to 5 percent of the population over the age of 65 years are 
suffering from AF. 1 The median age of a patient with AF is 75 years and 70% of the AF 
patients are aged 65 to 85 years of age. 2, 3 Disease management is challenged in elderly 
AF patients by frequent comorbidities including hypertension, congestive heart failure, 
left ventricular hypertrophy, coronary artery disease and diabetes mellitus placing them at 
increased risk for thromboembolic complications with AF, 4 side effects and pro-
arrhythmias.  
Radiofrequency catheter ablation is widely performed as an effective treatment for 
recurrent, drug-resistant AF. 5-8 Ablation techniques have improved and the complication 
rate has decreased. 9-12 As a result, referrals of elderly patients for catheter ablation of AF 
are on the rise. However, few elderly patients were included in prior AF catheter ablation 
studies. With increasing life expectancy, the elderly are the most rapidly expanding 
portion of our population making AF an even more important public health concern. 
Catheter ablation for the elderly could be an important treatment strategy after failed 
antiarrhythmic drug therapy. We aimed to assess feasibility, safety and outcome of AF 
catheter ablation procedure in an elderly patient population. 
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Methods 
Study patients: Consecutive patients over the age of 65 years with symptomatic 
paroxysmal and persistent AF undergoing a percutaneous catheter ablation procedure at 
the Royal Jubilee Hospital in Victoria B.C. (Canada) were included in this study. None of 
the patients had a significant structural heart disease. Demographic and clinical data were 
collected prior to the procedure. All patients gave informed consent prior to the 
procedure. 
Ablation Procedure. All patients underwent a wide-area circumferential pulmonary vein 
isolation for paroxysmal AF and additional linear lesions for persistent AF. For that 
purpose, three femoral vein sheaths were inserted under local anesthesia. A 6F steerable 
decapolar electrophysiology catheter LivewireTM (St. Jude Medical Inc., St. Paul, MN, 
USA) was placed into the coronary sinus. After double transseptal puncture performed 
using a BRKTM transseptal needle (St. Jude Medical Inc., St. Paul, MN, USA), a 5F 
circular decapolar catheter SCTM (St. Jude Medical Inc., St. Paul, MN, USA) and a 7F 
non-irrigated 4 mm tip bi-directional ablation catheter RF ConductrTM MC (Medtronic 
Inc., Minneapolis, MN, USA) were passed transseptally through two 8F transseptal 
guiding introducers SwartzTM SL1TM  (St. Jude Medical Inc., St. Paul, MN, USA). The 
catheter ablation was performed using radiofrequency energy under Ensite NavXTM 
mapping system (St. Jude Medical Inc., St. Paul, MN, USA) guidance.  
The ablation strategy consisted of continuous wide-area circumferential lines around both 
ipsilateral pulmonary veins. Lesions were delivered for 30 seconds, at 35 Watts for a 
maximum target temperature of 58° Celsius. For patients with persistent AF, additional 
Gelöscht: with 
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linear lesions were performed: a left atrial roof line connecting both upper left and right 
pulmonary veins and a left atrial isthmus line between the mitral valve annulus and the 
left inferior pulmonary vein. The additional left atrial lines were not routinely mapped 
and checked for conduction block and no ablation within the coronary sinus was 
performed. The endpoint of the procedure in both paroxysmal and persistent AF patients 
was electrical isolation of all pulmonary veins, which was assessed using the circular 
spiral catheter. No systematic mapping was performed in order to identify non-pulmonary 
vein or pulmonary vein triggers of AF. The procedure was performed under conscious 
sedation using midazolam and fentanyl.  This ablation protocol didn’t differ from the 
ablation approach in younger AF patients treated in our institution. 
Anticoagulation Strategy: Warfarin was discontinued three days prior to the procedure to 
allow INR to drop in a subtherapeutic range the day of the procedure (INR<2.0). After 
insertion of the transseptal catheters, therapeutic anticoagulation was initiated with a 
bolus of intravenous heparin (100 IU/kg bodyweight). Activated clotting time (ACT) was 
monitored in 30 minute intervals followed by additional boluses of heparin to keep the 
ACT with a target of 300 seconds. Oral anticoagulation was resumed on the same day of 
the procedure for at least 3 months.  
The clinical outcome after the ablation procedure was assessed using a patient assessment 
form at 6 months after the intervention (table 1).  
 
Results 
Gelöscht: The endpoint of 
the procedure was electrical 
isolation of all pulmonary veins, 
which was assessed using the 
circular Spiral catheter placed 
within the pulmonary vein.
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Out of a total of 230 consecutive AF ablation procedures, 45 patients were older than 65 
years of age and underwent 53 procedures. Of the 53 ablation procedures were 8 repeat 
procedures. The mean age of our population was 693.5 years. The patient characteristics 
are shown in table 2. All had a structurally normal heart.  The procedural characteristics 
are shown in table 3. The mean procedure time was 187 33 min. Acute procedural 
success rate with abolition of all pulmonary vein potentials was achieved in all patients. 
Pericardial effusion requiring percutaneous drainage occurred in one (1.9%) patient. 
There were neither acute nor late peripheral or cerebral thromboembolic events observed. 
None of the procedures were complicated by vascular access complications requiring 
transfusion or surgical interventions. Among the 43 patients whose clinical outcome was 
assessed at 6 months, 34 (79%) had a significant reduction of the total symptomatic AF 
episodes, compared to pre-ablation, with a complete lack of symptomatic AF in 32 (75%) 
patients and partial success (defined  as >90% improvement in symptoms) in the 
remaining 2 (4%). The success rate was higher for patients with paroxysmal versus 
persistent AF (81 vs. 67%). 6 patients (11 %) underwent repeated  procedures. 
 
Discussion 
The majority of AF patients seeking medical treatment are in the elderly age group which 
is often complicated by comorbidities making antiarrhythmic drug treatment difficult. 
Because of hypertension, congestive heart failure, left ventricular hypertrophy and 
coronary artery disease antiarrhythmic drug treatment often fails due to side effects, pro-
arrhythmia, or poor rhythm control. Since few years now radiofrequency catheter 
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ablation is widely performed as an effective treatment for recurrent, drug-refractory AF. 
However, few elderly patients were included in prior AF catheter ablation studies and the 
current guidelines for catheter ablation of AF recommend a conservative approach in the 
elderly patient population in the absence of clinical data. 13 
Our study results suggest that catheter ablation of AF in patients aged 65 years or more 
can be performed with success rates comparable to those in younger patients without an 
increase in complication rate. Successful maintenance of a stable sinus rhythm could be 
achieved in nearly 80% of this patient population with a mean age of 69 years. The rate 
for major complication was low with one patient (1.9 %) having an acute pericardial 
effusion requiring percutaneous drainage. No other major complications including death, 
thromboembolism, atrioesophageal fistula or vascular access complications occurred. 
Zado et al. 14 found similar success and complication rates in a patients age group over 65 
years. Interestingly, they were more likely to be women (up to 56% in the age group over 
75 years). Patients over age 80 years in the paper of Tan et al. 15 were less likely to 
undergo a repeat procedure than younger patients, but again the success and complication 
rates were not significantly different in the age group over 80 years than in those 60-69 
years (70% versus 74% for success rate). Another study by Bunch et al. 16 found also no 
increased risk of periprocedural complications in 35 patients aged 80 years and older.  
Limitations: This is an observational cohort study, and is not a prospective, randomized 
trial. In the absence of a direct randomized comparison of an invasive versus non-
invasive approach in the elderly AF patients, limited conclusions regarding outcome and 
safety of  the catheter ablation procedure in this population can be made. Furthermore, 
the freedom of AF was assessed based on symptoms reported by the patients only, and no 
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clear uniform long-term rhythm monitoring was performed in all patients (i.e. 7 day-
holter or implantable loop recorder). 
 
Conclusions 
 
Catheter ablation for AF can be performed in elderly patients group aged 65 years and 
more with normal hearts and predominantly paroxysmal AF, with comparable success 
and complication rate to those in younger patients. Therefore, ablation therapy should be 
considered as an appropriate therapeutic option for this patient group. Patients should not 
be excluded from undergoing AF catheter ablation on the basis of age alone. 
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Table 1: Patient assessment form 
 
1. Have you had any of the following symptoms?      
 
 Occasional skips and jumps in the heart?  Y / N   (please circle)  
 
 Regular racing heart beat?    Y / N  (please circle) 
 
 Irregular racing heart beat?    Y / N  (please circle) 
 
2. Please chart the amount of racing you have had below (months after ablation):  
 4th month 5th month 6th month 
Number of episodes?    
How long do they last?    
 
3. Did you require treatment in hospital?      medication only        electrical cardioversion 
 
4. Do they feel the same as before the procedure?    Y / N      (please circle)  
    If not, why? 
 
Not as fast     Symptoms not as bad 
 
 Regular (was irregular before)  Shorter duration 
 
Other………………………………………………………….. 
 
5. Overall, how do you feel compared to before the procedure?  (place a mark on the line) 
 
   Worse    Same      Improved by: 
                          50%        75%  90% 100%  
 
 
 
 
6. Are you or your doctor considering a repeat ablation procedure?  Y / N 
 
7. Are you taking fewer medications for AF than before the procedure? Y / N 
 
8. Are you still taking warfarin (also called coumadin)?   Y / N 
 
9. Have you had a pacemaker implanted since your ablation?  Y / N 
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Table 2: Patient characteristics 
 n=45 
Age (years) 693.5 
Sex (male) 35 (78%) 
Type of AF 
 Paroxysmal AF 
 Persistent AF 
 
39 (87%) 
6 (13%) 
History of AF (years) 8.76.5 
Number of AAD 1.380.77 
  
AAD=antiarrhythmic drug, LA=left atrium, EF=ejection fraction 
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Table 3: Procedural statistics 
  
n=53 
 
Average procedure time (minutes) 
 
18733 
  
Fluoroscopy time (minutes) 4312 
  
 
Major complications 
 Thromboembolic event and stroke 
 Pericardial tamponade 
 Vascular access complications 
 
 
none 
1 (1.9%) 
none  
 
ACT=activated clotting time, IU=international units 
 
 
 
 
 
